Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
356
resultados
Última actualización
04/10/2026 [07:34:00]
Resultados 300 a 325 de 356
Resumen de: US20260235622A1
0000 The present disclosure relates to use of GDF-15 as a novel biomarker for diagnosing, monitoring early-stage cancer, insulin resistance, and autoimmune diseases. Further, the present disclosure also relates to a multipurpose kit and personalized treatment across multiple health domains. Additionally, the present disclosure deals with an AI-driven personalized treatment and point of care (POC) platform using GDF-15 biomarker. There is a disclosure about dual biomarker system comprising GDF 15 and additional biomarker.
Resumen de: US20260232845A1
Methods and kits are provided for inhibiting inflammasome activation in cells of a subject or an inflammation-affected eye in a subject by administering to the subject a composition including a nucleotide sequence encoding a membrane independent CD59 protein operably linked to a promoter for expression and secretion of the membrane independent CD59 protein in the cells or the inflammation-affected eye, the composition inhibiting inflammasome activation.
Resumen de: US20260234272A1
Disclosed herein are inhibitors, such as antibodies, and antigen binding portions thereof, that selectively bind complexes of LTBP1-TGFβ1 and/or LTBP3-TGFβ1. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ1 activation, and treating subjects suffering from TGFβ1-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGFβ1 inhibitor for a subject in need thereof are also provided.
Resumen de: US20260234264A1
The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
Resumen de: US20260232812A1
0000 The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
Resumen de: US20260234206A1
0000 The present invention relates to proteins and protein libraries particularly for use in methods of screening to identify novel binding partners including diagnostic and therapeutic molecules.
Resumen de: US20260235612A1
0000 Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD163, CD91, CD59, MerTK and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.
Resumen de: US20260234551A1
0000 Provided is a genetically engineered human pluripotent stem cell line in which an insertion sequence including a nucleotide sequence of a fluorescent reporter gene is inserted following a stop codon of the TUBB3 gene, whereby the TUBB3 gene and the fluorescent reporter gene are co-expressed. Genetic manipulation is made to express the fluorescent reporter gene in response to the expression of the TUBB3 gene, a neural cell marker, so that when the cell line is differentiated into neural cells, the fluorescent signal is observed, thereby allowing for monitoring the differentiation process.
Resumen de: WO2025058005A1
Provided is a biomarker for use in the determination or diagnosis of a progression rate of amyotrophic lateral sclerosis (ALS) or a possibility of being affected by ALS and/or the selection or prediction of a therapeutic drug for ALS. There is discovered a biomarker selected from the group consisting of IL-17A, KLRD1, KRT19, NCF2, TFF2, YTHDF3, Th17, a regulatory T cell (Treg), mature CD8T, naive CD8T, exhausted CD8T, a Classical monocyte, memory CD4T, Th17/Treg, mature CD8T/naive CD8T, and mature CD8T/exhausted CD8T.
Resumen de: EP4790418A1
0001 The present invention refers to the diagnosis, prognosis, monitoring and/or treatment of comorbidities in people living with human immunodeficiency virus (HIV) (PLWH).
Resumen de: WO2024215624A2
This disclosure provides antibodies and methods for preparing and using the same wherein the antibodies bind to PTGFRN on a cell.
Resumen de: WO2021202793A2
Chimeric antigen receptors (CARs) with binding domains derived from a novel suite of CD33-binding antibodies are described. The CARs include optimized short and intermediate spacer regions. The current disclosure also provides methods of cell expansion/activation processes utilizing IL-2, IL-7, IL-15, and/or IL-21 that improve cellular proliferation and cell lysis of the CARs as described.
Resumen de: AU2012262122A1
The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
Resumen de: WO2021247009A1
A method of treating a cancer in a mammalian subject with a tumor signature characterized by any one or more of (i) a level of sirtuin (SIRT3) protein that is below a first predetermined threshold level, (ii) a level of manganese superoxide dismutase acetylated at the lysine 68 residue (AcK68) that exceeds a second predetermined threshold level, and (iii) expression levels of hypoxia-inducible factor 2α (HIF2α) that exceed a third predetermined threshold level indicative of lineage plasticity for stemness, the method comprising administering to the mammalian subject a therapeutically effective amount of a pentaaza macrocyclic ring complex corresponding to the Formula (I) below, optionally with administration of a further anti-cancer therapeutic agent.
Resumen de: WO2021236836A2
Methods of detecting a condition comprising neoangiogenesis, ischemia, or both, or risk thereof in a subject. Methods of inhibiting, ameliorating, delaying the onset of, reducing the likelihood of, treating, or preventing a condition comprising perfusion shortage (such as neoangiogenesis, ischemia, or both) in a subject in need thereof are described. Kits are described.
Resumen de: WO2018094116A1
Methods are provided of identifying a subject having impaired aldehyde dehydrogenase activity; and administering to the subject a compound comprising an isotopicaliy-modified polyunsaturated fatty acid, an isotopicaliy-modified polyunsaturated fatty acid ester, an isotopicaliy-modified polyunsaturated fatty acid thioester, an isotopicaliy-modified polyunsaturated fatty acid amide, a polyunsaturated fatty acid mimetic, or an isotopicaliy-modified polyunsaturated fatty acid pro-drug, the compound having an isotopic modification that reduces oxidation of the compound, thereby reducing production in the subject of substrate for aldehyde dehydrogenase. Some aspects provide coadministering an isotopicaliy-modified polyunsaturated fatty acid and an oxylipin.
Resumen de: WO2025106313A1
The present disclosure is related to compositions and methods for analyzing IgG antibody activity or activation of Fcγ receptors by certain antibodies. Also disclosed are transformed cells expressing human Fcγ receptors useful in methods for analyzing IgG antibody bioactivity.
Resumen de: CN122541562A
本申请涉及一种特异性识别磷酸化Tau217蛋白的单克隆抗体、其制备方法，以及包含该抗体的磷酸化Tau217蛋白检测试剂盒，该抗体可用于阿尔茨海默病的早期辅助诊断、病程监测及疗效评估。本发明试剂盒空白限为0.51 pg/mL，检出限为1.04 pg/mL，定量限为3.93 pg/mL，线性范围0.5‑100 pg/mL（线性相关系数r≥0.99），批内精密度CV≤8%，批间精密度CV≤15%，抗干扰性良好，试剂盒稳定性为12个月，开瓶后机载稳定期30天，与进口参比试剂盒相关性良好。
Resumen de: EP4790416A2
The present invention relates to a method comprising the step detecting in a sample an antibody binding specifically to NECAB1, an antibody binding specifically to NECAB1, a carrier such as a diagnostically useful carrier with a solid phase with an immobilized polypeptide comprising an antigen or at least one epitope thereof or a variant of the antigen or epitope thereof, wherein the antigen is NECAB1, and a use of the antibody for diagnosing an autoimmune disease or a cancer.
Resumen de: WO2025249975A1
The present invention relates to a novel compound for detecting amyloid-beta and a method for diagnosing degenerative brain disease using same, the compound represented by chemical formula 1 or a salt thereof, according to the present invention, being capable of specifically binding to amyloid-beta. The compound or a salt thereof has high selectivity and thus may detect amyloid-beta in plasma with high sensitivity despite interference in the detection due to the presence of other proteins in plasma, and may be utilized for diagnosing degenerative brain disease or screening a therapeutic agent for degenerative brain disease.
Resumen de: WO2025017127A1
Gp130 antigen-binding antibodies are disclosed which inhibit IL-6, IL-11, OSM, LIF, CNTF, CT-1 mediated signal and bind to the cytokine binding region. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, humanised antibodies and therapeutic methods using, the Gp130 antigen-binding antibodies.
Resumen de: WO2025026908A1
The present invention relates to methods of diagnosing whether a subject has endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain, to methods of determining the therapeutic effect of a treatment regimen for endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain, and methods of monitoring endometriosis, uterine/pelvic pathology and/or endometriosis and/or uterine/pelvic pathology associated neuropathic pain progression in a subject, by determining the amount or concentration of EphA1 in a sample of the subject, and comparing the determined level to a reference value.
Resumen de: WO2024192404A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Resumen de: CN122525111A
0001 本发明公开了一种血浆TRAIL水平检测在阿尔茨海默病检测中的应用，涉及生物医学检测技术领域；一种检测人血浆中肿瘤坏死因子相关凋亡诱导配体浓度的物质在制备用于辅助评估受试者阿尔茨海默病相关认知状态的试剂中的应用；所述应用包括：将受试者的血浆TRAIL浓度检测值与预设的参考值范围或诊断阈值进行比较，其中，当所述血浆TRAIL浓度高于用于区分AD与认知功能正常状态的第一诊断阈值时，为辅助判断所述受试者更可能处于AD状态而非CU状态提供信息。本发明基于血浆样本进行检测，仅需常规静脉采血，避免了腰椎穿刺的侵入性风险和PET成像的放射性暴露及高额费用。所使用的酶联免疫吸附测定等技术成熟、操作相对标准化。
Nº publicación: CN122525107A 07/08/2026
Solicitante:
中国医学科学院北京协和医院
Resumen de: CN122525107A
0001 本发明涉及生物标志物技术领域，尤其涉及C1酯酶抑制剂的岩藻糖含量检测试剂在制备2型遗传性血管水肿诊断产品中的应用。本发明发现C1酯酶抑制剂的岩藻糖基化水平与2型遗传性血管水肿具有显著相关性，可用于诊断2型遗传性血管水肿；经ROC曲线验证，C1酯酶抑制剂的岩藻糖基化水平对于2型遗传性血管水肿具有较好的诊断性能，且具有检测方便、所需时间短等优势，可单独或与其他标志物组合用于2型遗传性血管水肿诊断，在2型遗传性血管水肿诊断中具有较好的应用前景。
BOPI
Sede Electrónica
